Search

Author/Creator Bischof, Matthias

1. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). Issue 1 (1st January 2021)

Authors:
Dean, Rebecca; Jensen, Ivar; Cyr, Phil; Miller, Beckley; Maru, Benit; Sproule, Douglas M.; Feltner, Douglas E.; Wiesner, Thomas; Malone, Daniel C.; Bischof, Matthias; Toro, Walter; Dabbous, Omar
Journal:
Journal of market access & health policy
Issue:
Volume 9:Issue 1(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. (3rd October 2021)

Authors:
Bischof, Matthias; Lorenzi, Maria; Lee, Jennifer; Druyts, Eric; Balijepalli, Chakrapani; Dabbous, Omar
Journal:
Current medical research and opinion
Issue:
Volume 37:Number 10(2021)
Page Start:
1719
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗